Greenland Mines Secures Canadian Patent for Klotho Gene Therapy Targeting Neurodegenerative Diseases

Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.

The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The patent grant is a significant milestone for the company’s biotech division, which focuses on developing therapies for devastating neurological conditions.

Greenland Mines is a Nasdaq-listed company with two operating divisions: mining and biotech. The mining division focuses on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The biotech division includes Klotho’s lead candidate KLTO-202 for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

The issuance of the Canadian patent strengthens Greenland Mines' position in the gene therapy space. Klotho, often referred to as the “longevity gene,” has been linked to cognitive function and neuroprotection. By securing patent protection in Canada, the company now has IP coverage in key markets, including the U.S., China, and Europe. This could facilitate future partnerships and licensing deals as the company progresses its clinical programs. The patent includes claims for various delivery methods, which may offer flexibility in developing treatments for different neurological disorders.

Investors can find the latest news and updates relating to GRML in the company’s newsroom at https://ibn.fm/GRML. The full press release is available at https://ibn.fm/x2pHA.